Last 39 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -4.62 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.82 | 17.55 | 15.58 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -90.1% | -52.6% | — | |
| P/B Ratio | 3.20 | 3.19 | 3.84 | 2.11 | 2.97 | 2.67 | 1.77 | 0.83 | 1.56 | 1.73 | 1.20 | 2.41 | 1.41 | 0.35 | 0.63 | 0.50 | 0.20 | 0.37 | 0.43 | 0.73 | 0.94 |
| — | +19.4% | +116.2% | +153.5% | +90.1% | +54.6% | +47.8% | -65.4% | +10.8% | +393.9% | +90.8% | +377.9% | +590.9% | -5.0% | +46.9% | -30.7% | -78.4% | -69.3% | -75.2% | -62.7% | -76.7% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 100.0% | 100.0% | 100.0% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0% | 0.0% | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -411.4% | -1318.0% | -591.4% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +20.9% | -160.3% | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -406.7% | -1315.7% | -590.0% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +21.8% | -159.6% | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -109.9% | -15.1% | -14.6% | -20.5% | -25.0% | -19.2% | -14.3% | -18.2% | -28.0% | -18.2% | -12.4% | -14.4% | -15.0% | -13.6% | -14.2% | -15.2% | -8.5% | -13.4% | -14.4% | -12.9% | -8.6% |
| — | +21.6% | -2.5% | -12.5% | +10.6% | -5.8% | -15.1% | -26.3% | -86.5% | -33.4% | +12.4% | +5.2% | -75.9% | -1.9% | +1.8% | -18.2% | +1.0% | -71.4% | -89.5% | -46.6% | +68.9% | |
| ROA | -82.8% | -13.3% | -13.0% | -17.3% | -19.7% | -15.7% | -12.1% | -14.8% | -21.3% | -14.8% | -10.5% | -11.8% | -11.6% | -10.8% | -11.3% | -12.3% | -6.8% | -10.4% | -12.1% | -11.5% | -7.7% |
| — | +15.3% | -7.3% | -17.4% | +7.6% | -6.4% | -15.8% | -25.5% | -82.9% | -37.2% | +7.8% | +4.3% | -70.7% | -3.7% | +6.0% | -6.6% | +11.9% | -48.7% | -77.8% | -55.5% | +61.7% | |
| ROIC | -120.8% | -18.4% | -25.9% | -36.1% | -23.2% | -22.5% | -25.0% | -31.8% | -28.7% | -21.1% | -17.2% | -20.4% | -16.6% | -15.6% | -27.5% | -36.5% | -25.3% | -12.5% | -20.0% | -25.6% | -13.5% |
| — | +18.2% | -3.6% | -13.3% | +19.3% | -6.4% | -45.1% | -56.3% | -72.6% | -35.0% | +37.3% | +44.1% | +34.3% | -24.9% | -37.4% | -42.3% | -87.2% | +27.7% | +79.1% | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.12 | 0.06 | 0.05 | 0.06 | 0.12 | 0.10 | 0.09 | 0.08 | 0.18 | 0.15 | 0.13 | 0.12 | 0.21 | 0.19 | 0.17 | 0.15 | 0.13 | 0.18 | 0.15 | 0.01 | 0.01 |
| — | -43.0% | -39.6% | -31.2% | -33.3% | -32.0% | -31.8% | -34.5% | -15.2% | -20.4% | -21.8% | -18.9% | +54.0% | +3.7% | +8.6% | +1739.1% | +1261.2% | +1661.1% | +1215.0% | -55.1% | -74.6% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.14 | 11.99 | 13.82 | 13.10 | 6.14 | 6.74 | 9.34 | 10.89 | 5.20 | 7.85 | 13.45 | 14.94 | 8.94 | 9.38 | 10.56 | 9.39 | 9.76 | 8.72 | 7.85 | 9.13 | 9.43 |
| — | +78.0% | +48.1% | +20.3% | +18.1% | -14.2% | -30.6% | -27.1% | -41.8% | -16.3% | +27.5% | +59.0% | -8.4% | +7.6% | +34.5% | +2.8% | +3.5% | -17.7% | -30.6% | -24.0% | +45.3% | |
| Quick Ratio | 6.14 | 11.99 | 13.82 | 13.10 | 6.14 | 6.74 | 9.34 | 10.89 | 5.20 | 7.85 | 13.45 | 14.94 | 8.94 | 9.38 | 10.56 | 9.39 | 9.76 | 8.72 | 7.85 | 9.13 | 9.43 |
| — | +78.0% | +48.1% | +20.3% | +18.1% | -14.2% | -30.6% | -27.1% | -41.8% | -16.3% | +27.5% | +59.0% | -8.4% | +7.6% | +34.5% | +2.8% | +3.5% | -17.7% | -30.6% | -24.0% | +45.3% | |
| Interest Coverage | — | — | — | — | — | — | -657.00 | -576.68 | -566.96 | -398.09 | -283.91 | -254.82 | — | -196.92 | -220.88 | -247.51 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 39 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SLDB stock.
Solid Biosciences Inc.'s current P/E is -4.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Solid Biosciences Inc.'s business trajectory between earnings reports.